DU
FULC icon

Delphia (USA)’s Fulcrum Therapeutics FULC Stock Holding History

Delphia (USA)’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,895
Closed -$31.1K – 256
2023
Q1 		$31.1K Buy
10,895
+270
+3% +$2.42K 0.04% 257
2022
Q4 		$77.3K Buy
+10,625
New +$69.3K 0.09% 258
2022
Q3 		– Sell
-11,784
Closed -$58K – 333
2022
Q2 		$58K Buy
+11,784
New +$115K 0.04% 368

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Delphia (USA)'s FULC Position: Q2 2023 in Review

Delphia (USA) sold out of Fulcrum Therapeutics (FULC) in Q2 2023, closing a stake of 10,895 shares — an estimated $31.1K sold.

Delphia (USA) first reported a position in FULC in Q2 2022 and held it in 3 quarters. The position peaked at $77.3K in Q4 2022. 88 funds tracked by Wall St. Rank hold FULC as of Q2 2023.

  • Delphia (USA) reported no remaining Fulcrum Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Delphia (USA) sold 10,895 Fulcrum Therapeutics shares in Q2 2023, an estimated $31.1K.
  • Delphia (USA) first reported a position in Fulcrum Therapeutics in Q2 2022 and held it in 3 quarters.
  • Delphia (USA)'s Fulcrum Therapeutics position peaked at $77.3K in Q4 2022.
  • 88 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2023.

Based on Delphia (USA)'s 13F filing for Q2 2023, filed 14 Aug 2023.